Akuamma (Picralima nitida): what is known, what is not known, and what to watch out for

Akuamma is the seeds of a West African tree Picralima nitida, sold online as a plant alternative to opioids and kratom. The alkaloids contained in them do indeed bind to opioid receptors, which has been confirmed in the laboratory. The problem is that the latest and most accurate pharmacological study of these compounds undermines their pain-relieving effects, and there are no studies involving humans. There are also several claims circulating about this raw material's composition and legal status that have not been confirmed in any document and refer only to themselves online. This text shows what exactly was measured and by what method, what was not measured at all, what we have not confirmed at the source, and why you will not find any doses or numbers of seeds here.

KEY INFORMATION
• The alkaloids in the seeds bind to opioid receptors, but at micromolar concentrations; the authors of the measurement stated directly that they have neither high affinity nor selectivity.
• A 2021 study, which isolated six alkaloids and tested them on a panel of over 40 receptors, showed limited pain-relieving efficacy and directly undermines earlier reports and the traditional use of the seeds as a pain relief agent.
• There is no randomized clinical trial of akuamma in humans.
• We have not confirmed in documents that the seeds are approved for marketing as food in the European Union.
• Do not combine akuamma with opioids, benzodiazepines, or alcohol. Alarm symptoms: slow or shallow breathing, drowsiness from which it is difficult to awaken, blue lips. This is a life-threatening condition; call for help.
• This article does not provide doses because there is no source on which to base them.

What is akuamma and where does it come from?

Picralima nitida It is a tree from the Apocynaceae family, growing in the humid rainforests of West and Central Africa. Its fruits contain seeds that have been used in traditional medicine in Ghana, Nigeria, and Cameroon for pain, fever, and malaria. The commercial name akuamma refers specifically to these seeds, usually sold as a ground powder.

This tradition is real and well-documented ethnographically, but it is not evidence of efficacy in itself. A plant used for centuries may work, may work poorly, or may work completely differently than those who used it expected. Measurements determine this, and those for akuamma only appeared at the end of the twentieth century and provided a less clear picture than tradition suggested.

The raw material reached Europe and North America much later, in the segment of plants described as natural alternatives to opioids, alongside kratom. In 2026, an online survey describing the use of akuamma seeds in the United States was published, authored by Timmons and colleagues ( Journal of Psychoactive Drugs ). The mere fact that such a work was created speaks to the scale of interest. However, this is not a study of efficacy or safety, but a description of what users declare.DOI 10.1080/02791072.2026.2618033Which alkaloids of akuamma act on opioid receptors?

The answer comes from two studies, and their common conclusion is more cautious than the commercial narrative suggests. In 1998, Menzies and colleagues isolated five alkaloids from the seeds and tested them using radioligand binding and on isolated tissues (

). This is a measurement in vitro and on animal tissue, not in humans.Menzies i wsp., European Journal of Pharmacology 1998, PMID 9683021Preference for the mu receptor, Ki 0.6 micromolar; agonist, action blocked by naloxone.

Two conclusions from this table are often overlooked. First, akuamma and akuammicine are different compounds with opposing effects on the mu receptor, so confusing their names changes the meaning of the description to the opposite. Second, the Ki values here are micromolar, and the authors concluded their work with the statement that the studied alkaloids have neither high affinity nor selectivity for mu, delta, and kappa receptors. The statement about affinity comparable to morphine has no basis in this work. The occasionally mentioned pericine was detected in cell suspension cultures Picralima nitida, and not isolated from the seeds.

Does akuamma really relieve pain?

The best answer we have today is: probably not in the way tradition claims. In 2021, Creed's team developed an isolation method that allowed for the acquisition of six alkaloids from akuamma in high purity and in quantities sufficient for extensive research. Five of them were tested on a panel of over 40 central nervous system receptors and confirmed that their main target is opioid receptors. Akuammicine turned out to be a strong kappa receptor agonist, while three other alkaloids showed micromolar activity against the mu receptor.

However, the next step is decisive. Alkaloids acting on the mu receptor were subjected to pain relief tests and showed limited effectiveness in thermal nociception models. The authors stated outright that their results contradict previous reports of the pain-relieving properties of alkaloids Picralima nitida and the traditional use of seeds as a pain-relieving agent (Creed i wsp., Journal of Natural Products 2021, PMC7932029).

This does not mean that the seeds do nothing. It means that the most accurate available measurement does not confirm the reason people reach for them, and any perceived effect may result from kappa receptor stimulation, which causes sedation and dysphoria, rather than pain relief. All of this was measured in vitro and in animals. Nothing has been measured in humans.

Is it legal to sell akuamma as food in the European Union?

We have not been able to find a document that allows this, and that is an honest answer. The seeds Picralima nitida are not listed in the register of plant raw materials prohibited in dietary supplements maintained by the Chief Sanitary Inspectorate, but absence from the prohibition list is not permission. Under EU food law, an ingredient without documented history of significant consumption before May 15, 1997, requires separate approval as a novel food, and we have not confirmed the presence of akuamma among the approved novel foods.

Separately, two claims circulating around this raw material need to be clarified. The lists of controlled substances in Poland are an annex to the regulation of the Minister of Health, not to the Act on Counteracting Drug Addiction, so citing the Act as the source of the list is inaccurate. We also found no confirmation in the materials of the European Monitoring Centre for Drugs and Drug Addiction that akuamma is included in its early warning system; the only references led back to content replicated on the internet. Until such a document is read at the source, we do not claim that akuamma is legal or that it is monitored.

What do we not know about the safety of akuamma and when should we seek help?

We practically know nothing for sure. There are no randomized clinical trials, no data on toxic doses in humans, no studies on chronic use, no assessment of addictive potential in humans. There is also no data on use during pregnancy and breastfeeding. The absence of reported harm with a raw material that no one has systematically studied is not evidence of safety.

Call for medical help if anyone experiences slowed, shallow, or interrupted breathing, unarousable drowsiness, blue or gray lips and fingertips, or muscle flaccidity after taking akuamma. These are symptoms of respiratory depression, which is the mechanism through which opioids can be fatal. The risk increases significantly when combined with other substances that depress the central nervous system, so akuamma should not be combined with opioids, benzodiazepines, or alcohol. The nature of this interaction is additive: each of these substances individually suppresses breathing, and together they do so more strongly.

You will not find any milligram amounts or seed counts in this text, even though the title of the entry suggests dosing. The reason is simple. Providing a dose requires a source that has established what is safe, and such a source for akuamma does not exist. The values circulating on forums are user reports, not measurements, and with a substance acting on opioid receptors, the difference between the two can mean the difference between discomfort and respiratory arrest.

Frequently Asked Questions

What is akuamma and where does it come from?

Akuamma to handlowa nazwa nasion drzewa Picralima nitida from the family of toinaceae, growing in the rainforests of West and Central Africa. In traditional medicine in Ghana and Nigeria, they were used for pain, fever, and malaria. The seeds contain several indole alkaloids, some of which bind to opioid receptors.

How does akuamma affect pain?

The alkaloids in the seeds bind to mu and kappa opioid receptors, but at micromolar concentrations and without selectivity. A 2021 study showed limited pain-relieving efficacy and explicitly stated that the results contradict earlier reports and the traditional use of the seeds as a pain relief agent.

What is the safe dose of akuamma?

Its value has not been established, and there is no source that defines it. No randomized clinical trials have been conducted in humans, and there is no data on toxic doses or chronic use. For this reason, we do not provide any values. The numbers circulating on forums are user reports, not measurements.

Does akuamma cause addiction?

This has not been studied in humans. Substances acting on opioid receptors carry a theoretical risk of addiction, but in the case of akuamma, there is no data to confirm or exclude this. We have also not confirmed reports that akuamma is included in the European early warning system for new psychoactive substances.

What symptoms after akuamma require calling for help?

Slow, shallow, or interrupted breathing, drowsiness from which one cannot be awakened, blue or gray lips and fingertips, and muscle flaccidity. These are symptoms of respiratory depression and a life-threatening condition. The risk increases when combined with opioids, benzodiazepines, or alcohol.

Is akuamma legal in Poland?

We have not confirmed this in any document, and therefore we do not claim it. The seeds are not on the list of banned substances in dietary supplements, but the absence of a ban does not imply approval for marketing. An ingredient without a history of significant consumption in the EU before May 15, 1997, requires separate approval as a novel food.

We have described the comparison of the effectiveness and safety of opioids with alternatives in more detail in the text about cannabis and opioids in pain management. We discuss how the composition of substances from an uncertain source is examined in the material about drug-checkingu w Europie.

The article is informational and educational in nature and does not replace consultation with a doctor. If you are pregnant, breastfeeding, taking medications, or have chronic conditions, consult the use of supplements or herbs with a specialist.

Author: Michał Waluk · Opublikowano: 2026-07-06 · Aktualizacja: 2026-08-16